EP1986690A4 - ANTICORPS ANTI-FcRn UTILISES DANS LE TRAITEMENT D'ETATS AUTO/ALLO-IMMUNS - Google Patents
ANTICORPS ANTI-FcRn UTILISES DANS LE TRAITEMENT D'ETATS AUTO/ALLO-IMMUNSInfo
- Publication number
- EP1986690A4 EP1986690A4 EP07762598A EP07762598A EP1986690A4 EP 1986690 A4 EP1986690 A4 EP 1986690A4 EP 07762598 A EP07762598 A EP 07762598A EP 07762598 A EP07762598 A EP 07762598A EP 1986690 A4 EP1986690 A4 EP 1986690A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatement
- auto
- immune conditions
- fcrn antibodies
- allo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76215106P | 2006-01-25 | 2006-01-25 | |
US11/634,676 US7662928B2 (en) | 2003-08-08 | 2006-12-06 | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
PCT/US2007/001742 WO2007087289A2 (fr) | 2006-01-25 | 2007-01-23 | ANTICORPS ANTI-FcRn UTILISÉS DANS LE TRAITEMENT D'ÉTATS AUTO/ALLO-IMMUNS |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1986690A2 EP1986690A2 (fr) | 2008-11-05 |
EP1986690A4 true EP1986690A4 (fr) | 2009-05-13 |
Family
ID=39791300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07762598A Withdrawn EP1986690A4 (fr) | 2006-01-25 | 2007-01-23 | ANTICORPS ANTI-FcRn UTILISES DANS LE TRAITEMENT D'ETATS AUTO/ALLO-IMMUNS |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1986690A4 (fr) |
JP (1) | JP2009524664A (fr) |
CA (1) | CA2637929A1 (fr) |
WO (1) | WO2007087289A2 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009080764A2 (fr) * | 2007-12-20 | 2009-07-02 | Abylnx N.V. | Administration orale ou nasale de composés comprenant des séquences d'acides aminés |
AU2015200004B2 (en) * | 2008-04-25 | 2017-02-16 | Bioverativ Therapeutics Inc. | Antibodies against fcrn and use thereof |
EP3348573B1 (fr) * | 2008-04-25 | 2020-04-22 | Dyax Corp. | Procédé de production d'un anticorps contre fcrn |
CN103619353B (zh) * | 2011-06-02 | 2016-01-06 | 戴埃克斯有限公司 | Fc受体结合蛋白 |
GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
GB201320066D0 (en) * | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
RS64542B1 (sr) | 2014-04-30 | 2023-09-29 | Hanall Biopharma Co Ltd | Vezivanje antitela za fcrn za lečenje autoimunih bolesti |
US10336825B2 (en) | 2014-04-30 | 2019-07-02 | Hanall Biopharma Co., Ltd. | Antibody binding to FcRn for treating autoimmune diseases |
SI3250610T1 (sl) | 2015-01-30 | 2023-11-30 | Momenta Pharmaceuticals, Inc. | Protitelesa fcrn in načini njihove uporabe |
CN108025066B (zh) | 2015-05-12 | 2022-04-12 | Synt免疫公司 | 人源化亲和力成熟的抗FcRn抗体 |
GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
SG11201900813RA (en) | 2016-07-29 | 2019-02-27 | Momenta Pharmaceuticals Inc | Fcrn antibodies and methods of use thereof |
US20200140548A1 (en) * | 2017-06-15 | 2020-05-07 | UCB Biopharma SRL | Method for the treatment of immune thrombocytopenia |
US11773168B2 (en) | 2017-12-13 | 2023-10-03 | Momenta Pharmaceuticals, Inc. | FcRn antibodies and methods of use thereof |
KR20210078517A (ko) | 2018-10-16 | 2021-06-28 | 유씨비 바이오파마 에스알엘 | 중증근무력증의 치료 방법 |
US11926669B2 (en) | 2022-05-30 | 2024-03-12 | Hanall Biopharma Co., Ltd. | Anti-FcRn antibody or antigen binding fragment thereof with improved stability |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005013912A2 (fr) * | 2003-08-08 | 2005-02-17 | The Research Foundation Of State University Of Newyork | Anti-corps anti-fcrn destines au traitement de troubles auto/allo-immuns |
WO2006118772A2 (fr) * | 2005-04-29 | 2006-11-09 | The Jackson Laboratory | Anticorops de fcrn et utilisations |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6992234B2 (en) * | 2000-11-06 | 2006-01-31 | The Jackson Laboratory | FcRn-based therapeutics for the treatment of auto-immune disorders |
-
2007
- 2007-01-23 WO PCT/US2007/001742 patent/WO2007087289A2/fr active Application Filing
- 2007-01-23 JP JP2008552358A patent/JP2009524664A/ja active Pending
- 2007-01-23 CA CA002637929A patent/CA2637929A1/fr not_active Abandoned
- 2007-01-23 EP EP07762598A patent/EP1986690A4/fr not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005013912A2 (fr) * | 2003-08-08 | 2005-02-17 | The Research Foundation Of State University Of Newyork | Anti-corps anti-fcrn destines au traitement de troubles auto/allo-immuns |
WO2006118772A2 (fr) * | 2005-04-29 | 2006-11-09 | The Jackson Laboratory | Anticorops de fcrn et utilisations |
Non-Patent Citations (6)
Title |
---|
AKILESH SHREERAM ET AL: "The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 113, no. 9, 1 May 2004 (2004-05-01), pages 1328 - 1333, XP002417288, ISSN: 0021-9738 * |
HANSEN R J ET AL: "Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia", JOURNAL OF PHARMACEUTICAL SCIENCE, AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON.; US, vol. 92, no. 6, 1 June 2003 (2003-06-01), pages 1206 - 1215, XP009109898, ISSN: 0022-3549 * |
RAGHAVAN M ET AL: "ANALYSIS OF THE PH DEPENDENCE OF THE NEONATAL FC RECEPTOR/IMMUNOGLOBULIN G INTERACTION USING ANTIBODY AND RECEPTOR VARIANTS", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON, PA.; US, vol. 34, no. 45, 1 January 1995 (1995-01-01), pages 14649 - 14657, XP009044243, ISSN: 0006-2960 * |
RAGHAVAN MALINI ET AL: "The class I major histocompatibility complex related Fc receptor shows pH-dependent stability differences correlating with immunoglobulin binding and release", BIOCHEMISTRY, vol. 32, no. 33, 1993, pages 8654 - 8660, XP002520215, ISSN: 0006-2960 * |
STORY C M ET AL: "A MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I-LIKE FC RECEPTOR CLONED FROM HUMAN PLACENTA: POSSIBLE ROLE IN TRANSFER OF IMMUNOGLOBULIN G FROM MOTHER TO FETUS", JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, JP, vol. 180, 1 December 1994 (1994-12-01), pages 2377 - 2381, XP002943093, ISSN: 0022-1007 * |
YU ET AL: "MECHANISM OF INTRAVENOUS IMMUNE GLOBULIN THERAPY IN ANTIBODY-MEDIATED AUTOIMMUNE DISEASES", NEW ENGLAND JOURNAL OF MEDICINE, THE, MASSACHUSETTS MEDICAL SOCIETY, WALTHAM, MA, US, vol. 340, no. 3, 21 January 1999 (1999-01-21), pages 227/228, XP008055851, ISSN: 0028-4793 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007087289A2 (fr) | 2007-08-02 |
JP2009524664A (ja) | 2009-07-02 |
WO2007087289A3 (fr) | 2008-10-09 |
CA2637929A1 (fr) | 2007-08-02 |
EP1986690A2 (fr) | 2008-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1986690A4 (fr) | ANTICORPS ANTI-FcRn UTILISES DANS LE TRAITEMENT D'ETATS AUTO/ALLO-IMMUNS | |
HUS2200007I1 (hu) | CD19-re irányuló optimalizált antitestek | |
HK1253579A1 (zh) | 用於治療癌症的單克隆抗體 | |
HK1204994A1 (en) | Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity | |
HK1151305A1 (zh) | 用於治療癌症的針對密蛋白- 的單克隆抗體 | |
HK1122579A1 (en) | Uses of anti-cd40 antibodies | |
IL177602A0 (en) | Uses of anti-ctla-4 antibodies | |
ZA200809662B (en) | Modified humanised anti-interleukin-18 antibodies | |
EP2265129A4 (fr) | Purification d anticorps par chromatographie | |
IL229512A (en) | Anti-vegf antibodies | |
EP2331579A4 (fr) | Anticorps monoclonaux | |
HK1139956A1 (en) | Novel anti-cd38 antibodies for the treatment of cancer -cd38 | |
IL194776A0 (en) | Humanized c-kit antibody | |
PL2059533T3 (pl) | Przeciwciała wieloswoiste | |
EP1869192A4 (fr) | Rearrangement de l'infrastructure d'anticorps | |
GB0907684D0 (en) | Process for preparation of alkoxysilanes | |
GB0525541D0 (en) | Detection of antibodies | |
EP1976878A4 (fr) | Séquence d'une région varibale de l'anticorps stro-1 | |
EP2452196A4 (fr) | Purification d'anticorps monoclonaux | |
GB0604575D0 (en) | Construction of inductive components | |
GB0606276D0 (en) | Antibodies | |
GB0607376D0 (en) | Antibodies | |
SI2059533T1 (sl) | Multispecifična protitelesa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080822 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
R17D | Deferred search report published (corrected) |
Effective date: 20081009 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/563 20060101ALI20081105BHEP Ipc: G01N 33/53 20060101ALI20081105BHEP Ipc: C12P 21/08 20060101ALI20081105BHEP Ipc: C07K 16/28 20060101ALI20081105BHEP Ipc: A61K 39/395 20060101AFI20081105BHEP Ipc: G01N 33/577 20060101ALI20081105BHEP Ipc: G01N 33/564 20060101ALI20081105BHEP |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: FENG, JIN Inventor name: HANSEN, RYAN, J. Inventor name: BALTHASAR, JOSEPH, P. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090417 |
|
17Q | First examination report despatched |
Effective date: 20090717 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20091130 |